It is worth mentioning that while we have knowledge about various types of ncRNAs modulating ZEB1 expression in liver cancer for more than 10 years [53,54], and even longer in other tumors, reports on other posttranscriptional regulatory mechanisms such as RNA modifications (i.e., m6A) are as recent as 2025 [47], underscoring the novelty of a growing field in the past few years that will surely help to understand ZEB1’s role, not only in liver cancer but also many other pathological settings. Here, ZEB1 is linked to liver cancer.